ArticleCurrent oncology (Toronto, Ont.)2026
Tumour GDF-15 Expression and Clinical Outcomes in Intermediate-Risk Metastatic Clear-Cell Renal Cell Carcinoma Treated with Second-Line Nivolumab.
Orhun Akdogan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.